title: A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk.
abstract: Cardiometabolic risk describes a collection of risk factors, with a likely underlying pathophysiology, resulting in accelerated atherosclerosis and the terminal cardiovascular events of myocardial infarction and stroke. Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of hypertension and other cardiovascular diseases. Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometabolic components with limited disturbance in metabolic parameters. Nebivolol, a third-generation beta-blocker (BB), acts by increasing nitric oxide (NO) bioavailability. This property may be especially important in NO-deficient population, such as black people, in regulating both blood pressure control and glucose homeostasis.
authors.affiliation: Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA, icilma.fergus@mountsinai.org.
authors.forename: Icilma V
authors.initials: IV
authors.lastname: Fergus
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Connell
authors.forename: Keith C
authors.initials: KC
authors.lastname: Ferdinand
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005006:Ethnicity; D006801:Humans; D007333:Insulin Resistance; D000068577:Nebivolol / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000378:metabolism*; D009765:Obesity; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D014665:Vasodilator Agents; D000068577:Nebivolol; D009569:Nitric Oxide